FRESENIUS KABI USA FDA Approval NDA 214919

NDA 214919

FRESENIUS KABI USA

FDA Drug Application

Application #214919

Documents

Letter2022-04-22
Label2022-04-22

Application Sponsors

NDA 214919FRESENIUS KABI USA

Marketing Status

Prescription001

Application Products

001INJECTABLE;INTRAVENOUS, SUBCUTANEOUS0.6MG/3ML0GLYCOPYRROLATEGLYCOPYRROLATE

FDA Submissions

TYPE 5; Type 5 - New Formulation or New ManufacturerORIG1AP2022-04-21STANDARD

Submissions Property Types

ORIG1Null40

CDER Filings

FRESENIUS KABI USA
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 214919
            [companyName] => FRESENIUS KABI USA
            [docInserts] => ["",""]
            [products] => [{"drugName":"GLYCOPYRROLATE","activeIngredients":"GLYCOPYRROLATE","strength":"0.6MG\/3ML","dosageForm":"INJECTABLE;INTRAVENOUS, SUBCUTANEOUS","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
            [labels] => [{"actionDate":"04\/21\/2022","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/214919s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"04\/21\/2022","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 5 - New Formulation or New Manufacturer","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/214919s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/214919Orig1s000ltr.pdf\"}]","notes":">"}]
            [supplements] => 
            [actionDate] => 2022-04-21
        )

)

© 2022 FDA.report
This site is not affiliated with or endorsed by the FDA.